Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00275197 |
The major purpose of the study is to help determine whether giving the combination of Elzasonan with Zoloft to people with depression is a better treatment than taking Zoloft alone. This study will also compare the safety and tolerability of Elzasonan and Zoloft combination to Zoloft alone or placebo.
Condition | Intervention | Phase |
---|---|---|
Depressive Disorder, Major |
Drug: Sertraline and Elzasonan Combination Drug: Sertraline Drug: Placebo |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | An Eight-Week, Double-Blind, Group-Sequential Design, Placebo Controlled Trial To Evaluate The Safety And Efficacy Of The Co- Administration Of Sertraline And Elzasonan (CP-448,187) In Outpatients With Major Depressive Disorder |
Enrollment: | 262 |
Study Start Date: | December 2005 |
Study Completion Date: | July 2007 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
Pfizer Investigational Site | |
Beverly Hills, California, United States, 90210 | |
United States, Connecticut | |
Pfizer Investigational Site | |
Norwich, Connecticut, United States, 06360 | |
United States, New York | |
Pfizer Investigational Site | |
New York, New York, United States, 10023 | |
United States, Ohio | |
Pfizer Investigational Site | |
BEACHWOOD, Ohio, United States, 44122 | |
Chile, RM | |
Pfizer Investigational Site | |
Santiago, RM, Chile | |
Estonia | |
Pfizer Investigational Site | |
Tallinn, Estonia, 10614 | |
Pfizer Investigational Site | |
Pärnu, Estonia, 80012 | |
Estonia, Viljandi mk. | |
Pfizer Investigational Site | |
Viljandi, Viljandi mk., Estonia, 71024 | |
Russian Federation | |
Pfizer Investigational Site | |
Moscow, Russian Federation, 115522 | |
Pfizer Investigational Site | |
Moscow, Russian Federation, 123367 | |
Pfizer Investigational Site | |
Moscow, Russian Federation, 107076 | |
Pfizer Investigational Site | |
Smolensk, Russian Federation, 214018 | |
Pfizer Investigational Site | |
Rostov On Don, Russian Federation, 344010 | |
Pfizer Investigational Site | |
St Petersburg, Russian Federation, 190121 | |
Pfizer Investigational Site | |
St. Petersburg, Russian Federation, 197110 | |
Pfizer Investigational Site | |
St. Petersburg, Russian Federation, 193167 | |
Pfizer Investigational Site | |
St. Petersburg, Russian Federation, 192019 | |
Pfizer Investigational Site | |
St. Petersburg, Russian Federation, 191180 | |
Russian Federation, Leningrad region | |
Pfizer Investigational Site | |
Gatchina, Leningrad region, Russian Federation, 190121 |
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Study ID Numbers: | A7571001 |
Study First Received: | January 9, 2006 |
Last Updated: | October 30, 2008 |
ClinicalTrials.gov Identifier: | NCT00275197 |
Health Authority: | United States: Food and Drug Administration |
Depression Mental Disorders Mood Disorders Sertraline |
Depressive Disorder, Major Depressive Disorder Serotonin Behavioral Symptoms |
Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Disease Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Psychotropic Drugs Serotonin Uptake Inhibitors |
Pharmacologic Actions Pathologic Processes Serotonin Agents Therapeutic Uses Central Nervous System Agents Antidepressive Agents |